ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Monoamine oxidase B

Monoamine oxidase B

概要

Name:Monoamine oxidase B
Target Synonym:EC:1.4.3.4,EC 1.4.3,MAOB,Amine oxidase [flavin-containing] B,Monoamine Oxidase B,Monoamine Oxidase Type B,MAO-B,Adrenalin Oxidase,Tyramine Oxidase,MAO, Platelet,MAO, Brain,EC 1.4.3.4
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

ライセンス

Project Name Modality Therapeutic Area Indications Stage Right Available
Reversible MAOB Inhibitor Small molecule Neurological disease Parkinson's disease Phase I Global

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
MAB-H5547 Human Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme)
MAB-H5547-structure
MAB-H5547-sds
ACRO Quality

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rasagiline Mesylate Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 Approved Teva Azilect, Agilect EU Parkinson Disease Teva Bv 2005-02-21 Supranuclear Palsy, Progressive; Restless Legs Syndrome; Parkinson Disease; Dementia; Alzheimer Disease; Synucleinopathies; Multiple System Atrophy; REM Sleep Behavior Disorder Details
Selegiline Approved Mylan Nv, Somerset Inc Emsam United States Depressive Disorder, Major Somerset Pharmaceuticals Inc 2006-02-27 Tobacco Use Cessation; Depressive Disorder, Major; Tobacco Use Disorder; Amphetamine-Related Disorders; Cocaine-Related Disorders Details
Selegiline Hydrochloride FPF-1100; E-250 (free base) Approved Sanofi FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline Mainland China Parkinson Disease Chinoin Pharmaceutical And Chemical Works Co Ltd 1989-06-05 HIV Infections; Marijuana Abuse; Parkinson Disease; Cognition Disorders Details
Safinamide Methanesulfonate PNU-151774; FCE-26743; PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125 Approved Newron Pharmaceutical Xadago, Equfina EU Parkinson Disease Zambon Spa 2015-02-23 Kidney Diseases; Parkinson Disease; Hepatic Insufficiency; Dyskinesia, Drug-Induced; Multiple System Atrophy Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate P2B-001 Phase 3 Clinical Pharma Two B Ltd Parkinson Disease Details
Vafidemstat ORY-2001 Phase 2 Clinical Oryzon Genomics Sa Schizophrenia; Alzheimer Disease; Kabuki syndrome; Borderline Personality Disorder Details
Rasagiline transdermal patch (Teikoku Pharma) Phase 1 Clinical Teikoku Pharma Parkinson Disease Details
J-147 J-147 Phase 1 Clinical Salk Institute Alzheimer Disease Details
SKL-PD YKP-10461; SKL-PD Phase 1 Clinical SK Biopharmaceuticals Co Ltd Parkinson Disease Details
PXS-5131 PXS-5131 Innovent Biologics(Suzhou) Co Ltd, Pharmaxis Ltd Details

This web search service is supported by Google Inc.

totopphone